Regeneron Faces Securities Lawsuit Following Failed Melanoma Trial

The litigation targets Regeneron’s conduct between August 1, 2025, and May 15, 2026, centering on the company’s repeated public optimism regarding a combination therapy of Fianlimab and Libtayo. While management characterized the treatment as a potential blockbuster, the complaint alleges that Regeneron failed to disclose that the trial’s preliminary statistical assumptions were fundamentally flawed and unlikely to produce meaningful results.

Management previously attributed slowing event rates—the disease progression or deaths used to measure the study’s success—to the superior performance of the active treatment arms. However, the narrative shifted on April 29, 2026, when the company revealed a protocol change. By May 15, Regeneron admitted the trial failed to reach statistical significance. Hagens Berman, the firm leading the class action, claims the company intentionally obscured the therapy's poor performance to maintain market confidence. Investors who suffered losses during the class period have until September 14, 2026, to file for lead plaintiff status.